These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37275963)

  • 1. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy
    Slamon DJ; Fasching PA; Hurvitz S; Chia S; Crown J; Martín M; Barrios CH; Bardia A; Im SA; Yardley DA; Untch M; Huang CS; Stroyakovskiy D; Xu B; Moroose RL; Loi S; Visco F; Bee-Munteanu V; Afenjar K; Fresco R; Taran T; Chakravartty A; Zarate JP; Lteif A; Hortobagyi GN
    Ther Adv Med Oncol; 2023; 15():17588359231178125. PubMed ID: 37275963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    Slamon D; Lipatov O; Nowecki Z; McAndrew N; Kukielka-Budny B; Stroyakovskiy D; Yardley DA; Huang CS; Fasching PA; Crown J; Bardia A; Chia S; Im SA; Ruiz-Borrego M; Loi S; Xu B; Hurvitz S; Barrios C; Untch M; Moroose R; Visco F; Afenjar K; Fresco R; Severin I; Ji Y; Ghaznawi F; Li Z; Zarate JP; Chakravartty A; Taran T; Hortobagyi G
    N Engl J Med; 2024 Mar; 390(12):1080-1091. PubMed ID: 38507751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
    Schäffler H; Mergel F; Pfister K; Lukac S; Fink A; Veselinovic K; Rack B; Fink V; Leinert E; Dimpfl M; Englisch A; Tegeler CM; Seller A; Grischke EM; Hahn M; Volmer LL; Engler T; Frevert ML; Taran FA; Janni W; Brucker SY; Hartkopf AD; Dannehl D
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.
    Kanjanapan Y; Anderson W; Smith M; Green J; Chalker E; Craft P
    Clin Breast Cancer; 2024 Aug; ():. PubMed ID: 39294027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    Lu YS; Mahidin EIBM; Azim H; Eralp Y; Yap YS; Im SA; Rihani J; Gokmen E; El Bastawisy A; Karadurmus N; Lim YN; Lim CS; Duc LT; Chung WP; Babu KG; Penkov K; Bowles J; Alfaro TD; Wu J; Gao M; Slimane K; El Saghir NS
    J Clin Oncol; 2024 Aug; 42(23):2812-2821. PubMed ID: 38771995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
    Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
    Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
    Neven P; Fasching PA; Chia S; Jerusalem G; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Zarate JP; Wang Y; Chakravartty A; Wang C; Slamon DJ
    Breast Cancer Res; 2023 Aug; 25(1):103. PubMed ID: 37653397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
    N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
    Borstnar S; Palacova M; Łacko A; Timcheva C; Gal-Yam EN; Papazisis K; Beniak J; Kudela P; Rubovszky G
    Radiol Oncol; 2022 May; 56(2):238-247. PubMed ID: 35575587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
    Decker T; Lüdtke-Heckenkamp K; Melnichuk L; Hirmas N; Lübbe K; Zahn MO; Schmidt M; Denkert C; Lorenz R; Müller V; Zahm DM; Mundhenke C; Bauer S; Thill M; Seropian P; Filmann N; Loibl S
    Breast; 2023 Dec; 72():103575. PubMed ID: 37690320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
    Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
    Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
    Salvador Bofill J; Moreno Anton F; Rodriguez Sanchez CA; Galve Calvo E; Hernando Melia C; Ciruelos Gil EM; Vidal M; Jiménez-Rodriguez B; De la Cruz Merino L; Martínez Jañez N; Villanueva Vazquez R; de Toro Salas R; Anton Torres A; Alvarez Lopez IM; Gavila Gregori J; Quiroga Garcia V; Vicente Rubio E; De la Haba-Rodriguez J; Gonzalez-Santiago S; Diaz Fernandez N; Barnadas Molins A; Cantos Sanchez de Ibargüen B; Delgado Mingorance JI; Bellet Ezquerra M; de Casa S; Gimeno A; Martin M
    Breast; 2022 Dec; 66():77-84. PubMed ID: 36206609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Fasching PA; Hack CC; Nabieva N; Maass N; Aktas B; Kümmel S; Thomssen C; Wolf C; Kolberg HC; Brucker C; Janni W; Dall P; Schneeweiss A; Marme F; Sütterlin MW; Ruebner M; Theuser AK; Kellner S; Hofmann NM; Böhm S; Almstedt K; Lück HJ; Schmatloch S; Kalder M; Uleer C; Jurhasz-Böss I; Hanf V; Jackisch C; Müller V; Rack B; Belleville E; Wallwiener D; Rody A; Rauh C; Bayer CM; Uhrig S; Goossens C; Huebner H; Brucker SY; Hein A; Fehm TN; Häberle L
    Eur J Cancer; 2024 Sep; 209():114239. PubMed ID: 39059184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
    Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL
    J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
    Lu YS; Im SA; Colleoni M; Franke F; Bardia A; Cardoso F; Harbeck N; Hurvitz S; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; O'Regan R; Gasch C; Solovieff N; Wang C; Wang Y; Chakravartty A; Ji Y; Tripathy D
    Clin Cancer Res; 2022 Mar; 28(5):851-859. PubMed ID: 34965945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.